Using
knockin point mutations in mice, Dr. Rudolph has demonstrated that anxiolytic and sedative actions of benzodiazepines, such as diazepam (Valium), are mediated by two distinct GABAA receptor subtypes and can thus be targeted separately pharmacologically.